Assessing the impact on intestinal microbiome and clinical outcomes of antibiotherapy optimisation strategies in haematopoietic stem cell transplant recipients: study protocol for the prospective multicentre OptimBioma study

Silvia Jiménez-Jorge, Gema Labrador-Herrera, Clara M Rosso-Fernández, Nancy Rodríguez-Torres, María Eugenia Pachón-Ibáñez, Younes Smani, Francisco José Márquez-Malaver, Carmen Limón Ramos, Carlos Solano, Lourdes Vázquez-López, Mi Kwon, Joan Manuel Mora Barrios, Manuela Aguilar-Guisado, Ildefonso Espigado, GETH (Grupo Español de Trasplante Hematopoyético y Terapia Celular), Ariadna Pérez Martínez, Peña-Muñoz F, Rebeca Bailen Almorox, Lucrecia Yáñez, Silvia Jiménez-Jorge, Gema Labrador-Herrera, Clara M Rosso-Fernández, Nancy Rodríguez-Torres, María Eugenia Pachón-Ibáñez, Younes Smani, Francisco José Márquez-Malaver, Carmen Limón Ramos, Carlos Solano, Lourdes Vázquez-López, Mi Kwon, Joan Manuel Mora Barrios, Manuela Aguilar-Guisado, Ildefonso Espigado, GETH (Grupo Español de Trasplante Hematopoyético y Terapia Celular), Ariadna Pérez Martínez, Peña-Muñoz F, Rebeca Bailen Almorox, Lucrecia Yáñez

Abstract

Introduction: Haematopoietic stem cell transplantation (HSCT) is a life-saving treatment for a number of haematological diseases. Graft versus host disease (GVHD) is its main complication and hampers survival. There is strong evidence that intestinal microbiota diversity of the recipient may increase the risk of GVHD worsening survival. Antibiotic regimens used during the early phase of the transplant may influence clinical outcomes by reducing intestinal microbiota diversity. Present guidelines of European Conference on Infections in Leukaemia exhort to optimising antibiotic use in haematological patients including HSCT recipients. The present study aims to investigate if, in HSCT recipients, the optimisation of antibacterial use may preserve intestinal microbiota composition reducing the incidence and severity of acute GVHD and improving relevant clinical outcomes.

Methods and analysis: This is a prospective longitudinal observational study of two cohorts of HSCT recipients: (1) the intervention cohort includes patients treated in centres in which a predefined strategy of antibiotherapy optimisation is implemented, with the objective of optimising and reducing antibiotic administration according to clinical criteria and (2) the control cohort includes patients treated in centres in which a classic permissive strategy of antibiotic prophylaxis and treatment is used. Adult patient receiving a first HSCT as a treatment for any haematological condition are included. Clinical variables are prospectively recorded and up to five faecal samples are collected for microbiota characterisation at prestablished peritransplant time points. Patients are followed since the preconditioning phase throughout 1-year post-transplant and four follow-up visits are scheduled. Faecal microbiota composition and diversity will be compared between both cohorts along with acute GVHD incidence and severity, severe infections rate, mortality and overall and disease-free survival.

Ethics and dissemination: The study was approved between 2017 and 2018 by the Ethical Committees of participant centres. Study results will be disseminated through peer-reviewed journals and national and international scientific conferences.

Trial registration number: NCT03727113.

Keywords: antibiotics; graft versus host disease; hematopoietic stem cell transplantation; infections; microbiome; microbiota.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

References

    1. Docampo MD, Auletta JJ, Jenq RR. Emerging influence of the intestinal microbiota during allogeneic hematopoietic cell transplantation: control the gut and the body will follow. Biol Blood Marrow Transplant 2015;21:1360–6. 10.1016/j.bbmt.2015.02.016
    1. Vossen JM, Heidt PJ, van den Berg H, et al. . Prevention of infection and graft-versus-host disease by suppression of intestinal microflora in children treated with allogeneic bone marrow transplantation. Eur J Clin Microbiol Infect Dis 1990;9:14–23. 10.1007/BF01969527
    1. Beelen DW, Elmaagacli A, Müller KD, et al. . Influence of intestinal bacterial decontamination using metronidazole and ciprofloxacin or ciprofloxacin alone on the development of acute graft-versus-host disease after marrow transplantation in patients with hematologic malignancies: final results and long-term follow-up of an open-label prospective randomized trial. Blood 1999;93:3267–75. 10.1182/blood.V93.10.3267.410k22_3267_3275
    1. Taur Y, Xavier JB, Lipuma L, et al. . Intestinal domination and the risk of bacteremia in patients undergoing allogeneic hematopoietic stem cell transplantation. Clin Infect Dis 2012;55:905–14. 10.1093/cid/cis580
    1. Taur Y, Jenq RR, Perales M-A, et al. . The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation. Blood 2014;124:1174–82. 10.1182/blood-2014-02-554725
    1. Khoruts A, Hippen KL, Lemire AM, et al. . Toward revision of antimicrobial therapies in hematopoietic stem cell transplantation: target the pathogens, but protect the indigenous microbiota. Transl Res 2017;179:116–25. 10.1016/j.trsl.2016.07.013
    1. Ubeda C, Pamer EG. Antibiotics, microbiota, and immune defense. Trends Immunol 2012;33:459–66. 10.1016/j.it.2012.05.003
    1. Holler E, Butzhammer P, Schmid K, et al. . Metagenomic analysis of the stool microbiome in patients receiving allogeneic stem cell transplantation: loss of diversity is associated with use of systemic antibiotics and more pronounced in gastrointestinal graft-versus-host disease. Biol Blood Marrow Transplant 2014;20:640–5. 10.1016/j.bbmt.2014.01.030
    1. Aguilar-Guisado M, Espigado I, Martín-Peña A, et al. . Optimisation of empirical antimicrobial therapy in patients with haematological malignancies and febrile neutropenia (how long study): an open-label, randomised, controlled phase 4 trial. Lancet Haematol 2017;4:e573–83. 10.1016/S2352-3026(17)30211-9
    1. Averbuch D, Cordonnier C, Livermore DM, et al. . Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European conference on infections in leukemia (ECIL-4, 2011). Haematologica 2013;98:1836–47. 10.3324/haematol.2013.091330
    1. Averbuch D, Orasch C, Cordonnier C, et al. . European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European conference on infections in leukemia. Haematologica 2013;98:1826–35. 10.3324/haematol.2013.091025
    1. Heinz WJ, Buchheidt D, Christopeit M, et al. . Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients: guidelines of the infectious diseases Working Party (AGIHO) of the German Society of hematology and medical oncology (DGHO). Ann Hematol 2017;96:1775–92. 10.1007/s00277-017-3098-3
    1. Klindworth A, Pruesse E, Schweer T, et al. . Evaluation of general 16S ribosomal RNA gene PCR primers for classical and next-generation sequencing-based diversity studies. Nucleic Acids Res 2013;41:e1. 10.1093/nar/gks808
    1. Magoč T, Salzberg SL. Flash: fast length adjustment of short reads to improve genome assemblies. Bioinformatics 2011;27:2957–63. 10.1093/bioinformatics/btr507
    1. Pedregosa F, Varoquaux G, Gramfort A. Scikit-learn: machine learning in python. J Mach Learn Res 2011;12:2825–30.
    1. DeSantis TZ, Hugenholtz P, Larsen N, et al. . Greengenes, a chimera-checked 16S rRNA gene database and workbench compatible with ARB. Appl Environ Microbiol 2006;72:5069–72. 10.1128/AEM.03006-05
    1. Bolyen E, Rideout JR, Dillon MR, et al. . Author correction: reproducible, interactive, scalable and extensible microbiome data science using QIIME 2. Nat Biotechnol 2019;37:1091–57. 10.1038/s41587-019-0252-6
    1. Liao M, Xie Y, Mao Y, et al. . Comparative analyses of fecal microbiota in Chinese isolated Yao population, minority Zhuang and rural Han by 16sRNA sequencing. Sci Rep 2018;8:1142. 10.1038/s41598-017-17851-8
    1. Glucksberg H, Storb R, Fefer A, et al. . Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974;18:295–304. 10.1097/00007890-197410000-00001
    1. Elashoff JD. nQuery advisor version 6.01 user’s guide. Ireland: Statistical Solutions, Cork, 2005.
    1. Machin D, Campbell MJ. Statistical tables for the design of clinical trials. Blackwell scientific publications: Oxford, 1987.
    1. Fleiss JL, Tytun A, Ury HK. A simple approximation for calculating sample sizes for comparing independent proportions. Biometrics 1980;36:343–6. 10.2307/2529990
    1. McArdle BH, Anderson MJ. Fitting multivariate models to community data: a comment on distance‐based redundancy analysis. Ecology 2001;82:290–7. 10.1890/0012-9658(2001)082[0290:FMMTCD];2
    1. D'Agostino RB, Kwan H. Measuring effectiveness. what to expect without a randomized control group. Med Care 1995;33:95–105.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться